{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:07:43Z","timestamp":1793754463903,"version":"4.6.1"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100022824","name":"Sanofi Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40257-025-00917-z","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T02:16:08Z","timestamp":1738894568000},"page":"183-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Infections in Patients with Atopic Dermatitis and the Influence of Treatment"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-8190","authenticated-orcid":false,"given":"Maddalena","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-6993","authenticated-orcid":false,"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-2556","authenticated-orcid":false,"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":false,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5559-9722","authenticated-orcid":false,"given":"Paolo","family":"Romita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nicoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Matruglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-9788","authenticated-orcid":false,"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"1","key":"917_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis Nat Rev Dis Primers. 2018;4(1):1. https:\/\/doi.org\/10.1038\/s41572-018-0001-z.","journal-title":"Atopic dermatitis. Nat Rev Dis Primers."},{"issue":"2","key":"917_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/healthcare8020070","volume":"8","author":"S Beki\u0107","year":"2020","unstructured":"Beki\u0107 S, Martinek V, Talapko J, Majnari\u0107 L, Vasilj Mihaljevi\u0107 M, \u0160krlec I. Atopic dermatitis and comorbidity. Healthcare (Basel). 2020;8(2):70. https:\/\/doi.org\/10.3390\/healthcare8020070.","journal-title":"Healthcare (Basel)."},{"issue":"12","key":"917_CR3","doi-asserted-by":"publisher","first-page":"adv00161","DOI":"10.2340\/00015555-3511","volume":"100","author":"F Ali","year":"2020","unstructured":"Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):adv00161. https:\/\/doi.org\/10.2340\/00015555-3511.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"917_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2500\/aap.2017.38.4005","volume":"38","author":"AM Drucker","year":"2017","unstructured":"Drucker AM. Atopic dermatitis: Burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017;38(1):3\u20138. https:\/\/doi.org\/10.2500\/aap.2017.38.4005.","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"917_CR5","first-page":"174","volume":"104","author":"K Koszor\u00fa","year":"2019","unstructured":"Koszor\u00fa K, Borza J, Gul\u00e1csi L, S\u00e1rdy M. Quality of life in patients with atopic dermatitis. Cutis. 2019;104(3):174\u20137.","journal-title":"Cutis"},{"key":"917_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CCID.S91263","volume":"9","author":"PV Chernyshov","year":"2016","unstructured":"Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2016;9:159\u201366. https:\/\/doi.org\/10.2147\/CCID.S91263.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"917_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.31053\/1853.0605.v79.n4.36743","volume":"79","author":"C Echeverria","year":"2022","unstructured":"Echeverria C, Angles MV, Larralde M, Luna PC, Mazzuoccolo LD, Moreno P. Impact of atopic dermatitis on quality of life: a large web-based survey from Argentina. Rev Fac Cien Med Univ Nac Cordoba. 2022;79(4):369\u201373. https:\/\/doi.org\/10.31053\/1853.0605.v79.n4.36743.","journal-title":"Rev Fac Cien Med Univ Nac Cordoba"},{"key":"917_CR8","doi-asserted-by":"publisher","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-51. https:\/\/doi.org\/10.1016\/j.jaad.2013.10.010","DOI":"10.1016\/j.jaad.2013.10.010"},{"issue":"6","key":"917_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/bjd\/ljad053","volume":"188","author":"AM Drucker","year":"2023","unstructured":"Drucker AM. Atopic dermatitis in 2023 and beyond. Br J Dermatol. 2023;188(6):691\u20132. https:\/\/doi.org\/10.1093\/bjd\/ljad053.","journal-title":"Br J Dermatol"},{"key":"917_CR10","doi-asserted-by":"publisher","first-page":"adv13363","DOI":"10.2340\/actadv.v103.13363","volume":"103","author":"M Maurelli","year":"2023","unstructured":"Maurelli M, Chiricozzi A, Peris K, Gisondi P, Girolomoni G. Atopic dermatitis in the elderly population. Acta Derm Venereol. 2023;103:adv13363. https:\/\/doi.org\/10.2340\/actadv.v103.13363.","journal-title":"Acta Derm Venereol"},{"key":"917_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/354250","volume":"2014","author":"SF Thomsen","year":"2014","unstructured":"Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014: 354250. https:\/\/doi.org\/10.1155\/2014\/354250.","journal-title":"ISRN Allergy."},{"issue":"3","key":"917_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","volume":"51","author":"PY Ong","year":"2016","unstructured":"Ong PY, Leung DY. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329\u201337. https:\/\/doi.org\/10.1007\/s12016-016-8548-5.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"917_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","volume":"126","author":"V Wang","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3\u201312. https:\/\/doi.org\/10.1016\/j.anai.2020.08.002.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"917_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/der.0000000000000526","volume":"31","author":"Z Ren","year":"2020","unstructured":"Ren Z, Silverberg JI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections. Dermatitis. 2020;31(2):157\u201364. https:\/\/doi.org\/10.1097\/der.0000000000000526.","journal-title":"Dermatitis"},{"issue":"3","key":"917_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/pde.13828","volume":"36","author":"JK Sandhu","year":"2019","unstructured":"Sandhu JK, Salame N, Ehsani-Chimeh N, Armstrong AW. Economic burden of cutaneous infections in children and adults with atopic dermatitis. Pediatr Dermatol. 2019;36(3):303\u201310. https:\/\/doi.org\/10.1111\/pde.13828.","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"917_CR16","first-page":"590","volume":"101","author":"W Frazier","year":"2020","unstructured":"Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590\u20138.","journal-title":"Am Fam Physician"},{"key":"917_CR17","doi-asserted-by":"publisher","first-page":"204062232110667","DOI":"10.1177\/20406223211066728","volume":"13","author":"G Girolomoni","year":"2022","unstructured":"Girolomoni G, Bus\u00e0 VM. Flare management in atopic dermatitis: from definition to treatment. Ther Adv Chronic Dis. 2022;13:20406223211066730. https:\/\/doi.org\/10.1177\/20406223211066728.","journal-title":"Ther Adv Chronic Dis."},{"issue":"10247","key":"917_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"issue":"1","key":"917_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2133.2011.10541.x","volume":"166","author":"SC Cai","year":"2012","unstructured":"Cai SC, Chen H, Koh WP, et al. Filaggrin mutations are associated with recurrent skin infection in Singaporean Chinese patients with atopic dermatitis. Br J Dermatol. 2012;166(1):200\u20133. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10541.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"917_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ng.1017","volume":"44","author":"L Paternoster","year":"2011","unstructured":"Paternoster L, Standl M, Chen CM, et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet. 2011;44(2):187\u201392. https:\/\/doi.org\/10.1038\/ng.1017.","journal-title":"Nat Genet"},{"issue":"12","key":"917_CR21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","volume":"39","author":"MR Mack","year":"2018","unstructured":"Mack MR, Kim BS. The itch-scratch cycle: a neuroimmune perspective. Trends Immunol. 2018;39(12):980\u201391. https:\/\/doi.org\/10.1016\/j.it.2018.10.001.","journal-title":"Trends Immunol"},{"issue":"3","key":"917_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/vaccines9030303","volume":"9","author":"S Garcovich","year":"2021","unstructured":"Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021;9(3):303. https:\/\/doi.org\/10.3390\/vaccines9030303.","journal-title":"Vaccines (Basel)."},{"issue":"5","key":"917_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm.2755","volume":"18","author":"SJ Galli","year":"2012","unstructured":"Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693\u2013704. https:\/\/doi.org\/10.1038\/nm.2755.","journal-title":"Nat Med"},{"issue":"6","key":"917_CR24","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/bjd.18643","volume":"182","author":"H Alexander","year":"2020","unstructured":"Alexander H, Paller AS, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol. 2020;182(6):1331\u201342. https:\/\/doi.org\/10.1111\/bjd.18643.","journal-title":"Br J Dermatol"},{"issue":"2","key":"917_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2020.07.111","volume":"84","author":"C Droitcourt","year":"2021","unstructured":"Droitcourt C, Vittrup I, Kerbrat S, Egeberg A, Thyssen JP. Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study. J Am Acad Dermatol. 2021;84(2):290\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.111.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"917_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ijd.12198","volume":"53","author":"CL Jinnest\u00e5l","year":"2014","unstructured":"Jinnest\u00e5l CL, Belfrage E, B\u00e4ck O, Schmidtchen A, Sonesson A. Skin barrier impairment correlates with cutaneous Staphylococcus aureus colonization and sensitization to skin-associated microbial antigens in adult patients with atopic dermatitis. Int J Dermatol. 2014;53(1):27\u201333. https:\/\/doi.org\/10.1111\/ijd.12198.","journal-title":"Int J Dermatol"},{"issue":"3","key":"917_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5604\/17331331.1215600","volume":"65","author":"A Buda","year":"2016","unstructured":"Buda A, Mi\u0119dzobrodzki J. The role of Staphylococcus aureus in secondary infections in patients with atopic dermatitis (ad). Pol J Microbiol. 2016;65(3):253\u20139. https:\/\/doi.org\/10.5604\/17331331.1215600.","journal-title":"Pol J Microbiol"},{"issue":"21","key":"917_CR28","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1158\/1078-0432.Ccr-14-0707","volume":"20","author":"K Wolk","year":"2014","unstructured":"Wolk K, Mitsui H, Witte K, et al. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: Role of Th2-mediated biased Th17 function. Clin Cancer Res. 2014;20(21):5507\u201316. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-0707.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"917_CR29","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.4049\/jimmunol.174.12.8003","volume":"174","author":"S Rieg","year":"2005","unstructured":"Rieg S, Steffen H, Seeber S, et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol. 2005;174(12):8003\u201310. https:\/\/doi.org\/10.4049\/jimmunol.174.12.8003.","journal-title":"J Immunol"},{"issue":"4","key":"917_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000339180","volume":"224","author":"MT Fierro","year":"2012","unstructured":"Fierro MT, Banche G, Marenco F, et al. Functional and phenotypical impairment of polymorphonuclear cells in atopic dermatitis: an additional cause for the known susceptibility to infections? Dermatology. 2012;224(4):323\u201330. https:\/\/doi.org\/10.1159\/000339180.","journal-title":"Dermatology"},{"issue":"1","key":"917_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/bjd.19825","volume":"185","author":"C Droitcourt","year":"2021","unstructured":"Droitcourt C, Vittrup I, Dupuy A, Egeberg A, Thyssen JP. Risk of systemic infections requiring hospitalization in children with atopic dermatitis: a Danish retrospective nationwide cohort study. Br J Dermatol. 2021;185(1):119\u201329. https:\/\/doi.org\/10.1111\/bjd.19825.","journal-title":"Br J Dermatol"},{"key":"917_CR32","doi-asserted-by":"publisher","first-page":"7621217","DOI":"10.1155\/2020\/7621217","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li Y, Xu W, Li L. Risk factors in outpatients with dermatitis and eczema in tertiary hospitals of China who have clinically suspected bacterial infection. Biomed Res Int. 2020;2020:7621217. https:\/\/doi.org\/10.1155\/2020\/7621217.","journal-title":"Biomed Res Int"},{"issue":"4","key":"917_CR33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaad.2018.11.028","volume":"80","author":"L Serrano","year":"2019","unstructured":"Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(4):904\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.028.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"917_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/21505594.2020.1869484","volume":"12","author":"FS Cavalcante","year":"2021","unstructured":"Cavalcante FS, Saintive S, Carvalho Ferreira D, et al. Methicillin-resistant Staphylococcus aureus from infected skin lesions present several virulence genes and are associated with the CC30 in Brazilian children with atopic dermatitis. Virulence. 2021;12(1):260\u20139. https:\/\/doi.org\/10.1080\/21505594.2020.1869484.","journal-title":"Virulence."},{"issue":"1\u20133","key":"917_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12026-014-8539-7","volume":"59","author":"CS Stach","year":"2014","unstructured":"Stach CS, Herrera A, Schlievert PM. Staphylococcal superantigens interact with multiple host receptors to cause serious diseases. Immunol Res. 2014;59(1\u20133):177\u201381. https:\/\/doi.org\/10.1007\/s12026-014-8539-7.","journal-title":"Immunol Res"},{"issue":"1","key":"917_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1034\/j.1399-3038.2003.02105.x","volume":"14","author":"R Bunikowski","year":"2003","unstructured":"Bunikowski R, Mielke M, Br\u00e4utigam M, Renz H, Wahn U. Effect of oral cyclosporin A in children with Staphylococcus aureus-colonized vs S aureus-infected severe atopic dermatitis. Pediatr Allergy Immunol. 2003;14(1):55\u20139. https:\/\/doi.org\/10.1034\/j.1399-3038.2003.02105.x.","journal-title":"Pediatr Allergy Immunol"},{"issue":"8","key":"917_CR37","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/jid.2014.43","volume":"134","author":"AM Brauweiler","year":"2014","unstructured":"Brauweiler AM, Goleva E, Leung DYM. Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol. 2014;134(8):2114\u201321. https:\/\/doi.org\/10.1038\/jid.2014.43.","journal-title":"J Invest Dermatol"},{"issue":"7476","key":"917_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nature12655","volume":"503","author":"Y Nakamura","year":"2013","unstructured":"Nakamura Y, Oscherwitz J, Cease KB, et al. Staphylococcus \u03b4-toxin induces allergic skin disease by activating mast cells. Nature. 2013;503(7476):397\u2013401. https:\/\/doi.org\/10.1038\/nature12655.","journal-title":"Nature"},{"issue":"11","key":"917_CR39","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1128\/iai.00593-13","volume":"81","author":"C Giai","year":"2013","unstructured":"Giai C, Gonzalez C, Ledo C, et al. Shedding of tumor necrosis factor receptor 1 induced by protein A decreases tumor necrosis factor alpha availability and inflammation during systemic Staphylococcus aureus infection. Infect Immun. 2013;81(11):4200\u20137. https:\/\/doi.org\/10.1128\/iai.00593-13.","journal-title":"Infect Immun"},{"issue":"1","key":"917_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jaci.2009.09.052","volume":"125","author":"JB Travers","year":"2010","unstructured":"Travers JB, Kozman A, Mousdicas N, et al. Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid. J Allergy Clin Immunol. 2010;125(1):146-52.e1-2. https:\/\/doi.org\/10.1016\/j.jaci.2009.09.052.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"917_CR41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/cea.13820","volume":"51","author":"H Yue","year":"2021","unstructured":"Yue H, Umehara Y, Trujillo-Paez JV, et al. Exogenous factors in the pathogenesis of atopic dermatitis: irritants and cutaneous infections. Clin Exp Allergy. 2021;51(3):382\u201392. https:\/\/doi.org\/10.1111\/cea.13820.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"917_CR42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/jid.2009.243","volume":"130","author":"AL Cogen","year":"2010","unstructured":"Cogen AL, Yamasaki K, Sanchez KM, et al. Selective antimicrobial action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal resident of the skin. J Invest Dermatol. 2010;130(1):192\u2013200. https:\/\/doi.org\/10.1038\/jid.2009.243.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"917_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/jid.2013.291","volume":"134","author":"T Volz","year":"2014","unstructured":"Volz T, Skabytska Y, Guenova E, et al. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol. 2014;134(1):96\u2013104. https:\/\/doi.org\/10.1038\/jid.2013.291.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"917_CR44","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jaip.2014.04.007","volume":"2","author":"PY Ong","year":"2014","unstructured":"Ong PY. Recurrent MRSA skin infections in atopic dermatitis. J Allergy Clin Immunol Pract. 2014;2(4):396\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2014.04.007.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"917_CR45","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.20887","volume":"186","author":"J Wan","year":"2022","unstructured":"Wan J, Shin DB, Syed MN, Abuabara K, Lemeshow AR, Gelfand JM. Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study. Br J Dermatol. 2022;186(4):664\u201372. https:\/\/doi.org\/10.1111\/bjd.20887.","journal-title":"Br J Dermatol"},{"issue":"4","key":"917_CR46","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jaci.2011.02.010","volume":"127","author":"DY Leung","year":"2011","unstructured":"Leung DY, Gao PS, Grigoryev DN, et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-\u03b3 response. J Allergy Clin Immunol. 2011;127(4):965-73.e1-5. https:\/\/doi.org\/10.1016\/j.jaci.2011.02.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"917_CR47","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaci.2011.06.003","volume":"128","author":"MD Howell","year":"2011","unstructured":"Howell MD, Gao P, Kim BE, et al. The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. J Allergy Clin Immunol. 2011;128(5):1006\u201314. https:\/\/doi.org\/10.1016\/j.jaci.2011.06.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"917_CR48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jaci.2009.05.020","volume":"124","author":"LA Beck","year":"2009","unstructured":"Beck LA, Boguniewicz M, Hata T, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009;124(2):260-9.e7. https:\/\/doi.org\/10.1016\/j.jaci.2009.05.020.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"917_CR49","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/sj.jid.5700657","volume":"127","author":"WM Peng","year":"2007","unstructured":"Peng WM, Jenneck C, Bussmann C, et al. Risk factors of atopic dermatitis patients for eczema herpeticum. J Invest Dermatol. 2007;127(5):1261\u20133. https:\/\/doi.org\/10.1038\/sj.jid.5700657.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"917_CR50","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1067\/S0190-9622(03)00896-X","volume":"49","author":"A Wollenberg","year":"2003","unstructured":"Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol. 2003;49(2):198\u2013205. https:\/\/doi.org\/10.1067\/S0190-9622(03)00896-X.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"917_CR51","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2003.07.001","volume":"112","author":"A Wollenberg","year":"2003","unstructured":"Wollenberg A, Wetzel S, Burgdorf WHC, Haas J. Viral infections in atopic dermatitis: Pathogenic aspects and clinical management. J Allergy Clin Immunol. 2003;112(4):667\u201374. https:\/\/doi.org\/10.1016\/j.jaci.2003.07.001.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"917_CR52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000069968","volume":"206","author":"AF Nikkels","year":"2003","unstructured":"Nikkels AF, Pi\u00e9rard GE. Framing the future of antifungals in atopic dermatitis. Dermatology. 2003;206(4):398\u2013400. https:\/\/doi.org\/10.1159\/000069968.","journal-title":"Dermatology"},{"issue":"5","key":"917_CR53","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jaci.2005.01.065","volume":"115","author":"P Schmid-Grendelmeier","year":"2005","unstructured":"Schmid-Grendelmeier P, Fl\u00fcckiger S, Disch R, et al. IgE-mediated and T cell\u2013mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol. 2005;115(5):1068\u201375. https:\/\/doi.org\/10.1016\/j.jaci.2005.01.065.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"917_CR54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaci.2011.02.043","volume":"128","author":"H Balaji","year":"2011","unstructured":"Balaji H, Heratizadeh A, Wichmann K, et al. Malassezia sympodialis thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis. J Allergy Clin Immunol. 2011;128(1):92-9.e4. https:\/\/doi.org\/10.1016\/j.jaci.2011.02.043.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"917_CR55","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1365-2133.2007.08193.x","volume":"157","author":"Y Takahata","year":"2007","unstructured":"Takahata Y, Sugita T, Kato H, Nishikawa A, Hiruma M, Muto M. Cutaneous Malassezia flora in atopic dermatitis differs between adults and children. Br J Dermatol. 2007;157(6):1178\u201382. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08193.x.","journal-title":"Br J Dermatol"},{"key":"917_CR56","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/849206","volume":"2015","author":"G Javad","year":"2015","unstructured":"Javad G, Taheri Sarvtin M, Hedayati MT, Hajheydari Z, Yazdani J, Shokohi T. Evaluation of Candida colonization and specific humoral responses against Candida albicans in patients with atopic dermatitis. Biomed Res Int. 2015;2015: 849206. https:\/\/doi.org\/10.1155\/2015\/849206.","journal-title":"Biomed Res Int"},{"issue":"6","key":"917_CR57","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","volume":"137","author":"SM Langan","year":"2017","unstructured":"Langan SM, Abuabara K, Henrickson SE, Hoffstad O, Margolis DJ. Increased risk of cutaneous and systemic infections in atopic dermatitis-a cohort study. J Invest Dermatol. 2017;137(6):1375\u20137. https:\/\/doi.org\/10.1016\/j.jid.2017.01.030.","journal-title":"J Invest Dermatol"},{"key":"917_CR58","first-page":"96","volume":"66","author":"H Rotsztejn","year":"2012","unstructured":"Rotsztejn H, Frankowska J, Kamer B, Trznadel-Grodzka E. Infection cases in infants and small children with atopic dermatitis\u2013Own observations. Postepy Hig Med Dosw (Online). 2012;66:96\u2013103.","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"4","key":"917_CR59","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jaci.2013.08.012","volume":"133","author":"JI Silverberg","year":"2014","unstructured":"Silverberg JI, Silverberg NB. Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study. J Allergy Clin Immunol. 2014;133(4):1041\u20137. https:\/\/doi.org\/10.1016\/j.jaci.2013.08.012.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"917_CR60","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.anai.2017.10.019","volume":"120","author":"S Narla","year":"2018","unstructured":"Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. Ann Allergy Asthma Immunol. 2018;120(1):66-72e11. https:\/\/doi.org\/10.1016\/j.anai.2017.10.019.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"917_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/1744666X.2021.1919511","volume":"17","author":"M Marko","year":"2021","unstructured":"Marko M, Pawliczak R. Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies. Expert Rev Clin Immunol. 2021;17(6):619\u201327. https:\/\/doi.org\/10.1080\/1744666X.2021.1919511.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"917_CR62","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","volume":"78","author":"SH Yu","year":"2018","unstructured":"Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733-40e11. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.074.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"917_CR63","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1093\/rheumatology\/kead083","volume":"62","author":"A Barbulescu","year":"2023","unstructured":"Barbulescu A, Sjolander A, Delcoigne B, Askling J, Frisell T. Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application. Rheumatology (Oxford). 2023;62(10):3391\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kead083.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"917_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","volume":"42","author":"J Youssef","year":"2016","unstructured":"Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin N Am. 2016;42(1):157\u201376. https:\/\/doi.org\/10.1016\/j.rdc.2015.08.004. (ix-x).","journal-title":"Rheum Dis Clin N Am."},{"issue":"6","key":"917_CR65","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378. https:\/\/doi.org\/10.1111\/jdv.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"917_CR66","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5021\/ad.2010.22.2.170","volume":"22","author":"SW Kim","year":"2010","unstructured":"Kim SW, Park YW, Kwon IH, Kim KH. Cyclosporin treatment of atopic dermatitis: is it really associated with infectious diseases? Ann Dermatol. 2010;22(2):170\u20132. https:\/\/doi.org\/10.5021\/ad.2010.22.2.170.","journal-title":"Ann Dermatol"},{"issue":"5","key":"917_CR67","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jmii.2018.12.014","volume":"53","author":"ED Abad","year":"2020","unstructured":"Abad ED, Ferreira DC, Cavalcante FS, et al. High incidence of acquiring methicillin-resistant Staphylococcus aureus in Brazilian children with atopic dermatitis and associated risk factors. J Microbiol Immunol Infect. 2020;53(5):724\u201330. https:\/\/doi.org\/10.1016\/j.jmii.2018.12.014.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"917_CR68","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1525-1470.2011.01488.x","volume":"28","author":"WT Waxweiler","year":"2011","unstructured":"Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28(6):689\u201394. https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01488.x.","journal-title":"Pediatr Dermatol"},{"issue":"8","key":"917_CR69","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/09546634.2019.1642996","volume":"31","author":"K Phan","year":"2020","unstructured":"Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat. 2020;31(8):810\u20134. https:\/\/doi.org\/10.1080\/09546634.2019.1642996.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"917_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2230.2006.02290.x","volume":"32","author":"ML Murray","year":"2007","unstructured":"Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol. 2007;32(1):23\u20137. https:\/\/doi.org\/10.1111\/j.1365-2230.2006.02290.x.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"917_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/pde.14909","volume":"39","author":"AS Paller","year":"2022","unstructured":"Paller AS, Beck LA, Blauvelt A, et al. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data. Pediatr Dermatol. 2022;39(2):187\u201396. https:\/\/doi.org\/10.1111\/pde.14909.","journal-title":"Pediatr Dermatol"},{"key":"917_CR72","unstructured":"US Food & Drug Administration. FDA approves new eczema drug Dupixent. 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-eczema-drug-dupixent. Accessed 26 Apr 2024."},{"key":"917_CR73","unstructured":"European Medicines Agency. Dupixent summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed 26 Apr 2024."},{"issue":"3","key":"917_CR74","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","volume":"20","author":"LF Eichenfield","year":"2019","unstructured":"Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443\u201356. https:\/\/doi.org\/10.1007\/s40257-019-00445-7.","journal-title":"Am J Clin Dermatol"},{"key":"917_CR75","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","volume":"54","author":"Z Ou","year":"2018","unstructured":"Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303\u201310. https:\/\/doi.org\/10.1016\/j.intimp.2017.11.031.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"917_CR76","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393\u2013408. https:\/\/doi.org\/10.1007\/s40257-022-00685-0.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"917_CR77","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck LA, Thaci D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567\u201377. https:\/\/doi.org\/10.1007\/s40257-020-00527-x.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"917_CR78","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaad.2020.05.128","volume":"83","author":"AL Bosma","year":"2020","unstructured":"Bosma AL, de Wijs LEM, Hof MH, et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol. 2020;83(5):1375\u201384. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.128.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"917_CR79","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjd.19460","volume":"184","author":"MJ Cork","year":"2021","unstructured":"Cork MJ, Thaci D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged \u2265 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857\u201370. https:\/\/doi.org\/10.1111\/bjd.19460.","journal-title":"Br J Dermatol"},{"issue":"5","key":"917_CR80","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/pde.14799","volume":"38","author":"PL McKenzie","year":"2021","unstructured":"McKenzie PL, Rangu S, Treat JR, Castelo-Soccio L. Experience using dupilumab for pediatric atopic dermatitis at a tertiary care center: inadequate response and adverse events. Pediatr Dermatol. 2021;38(5):1178\u201384. https:\/\/doi.org\/10.1111\/pde.14799.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"917_CR81","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12325-022-02322-y","volume":"40","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Wollenberg A, Eichenfield LF, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab. Adv Ther. 2023;40(1):367\u201380. https:\/\/doi.org\/10.1007\/s12325-022-02322-y.","journal-title":"Adv Ther"},{"issue":"4","key":"917_CR82","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","volume":"84","author":"Y Wang","year":"2021","unstructured":"Wang Y, Jorizzo JL. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration. J Am Acad Dermatol. 2021;84(4):1010\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"917_CR83","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/1744666X.2023.2271666","volume":"20","author":"M Marko","year":"2024","unstructured":"Marko M, Pawliczak R. Skin infections during dupilumab monotherapy in moderate-to-severe atopic dermatitis - A meta-analysis of randomized clinical trials. Expert Rev Clin Immunol. 2024;20(1):121\u201334. https:\/\/doi.org\/10.1080\/1744666X.2023.2271666.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"917_CR84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","volume":"78","author":"P Fleming","year":"2018","unstructured":"Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62-9e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.052.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"917_CR85","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/all.15811","volume":"78","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Guttman-Yassky E, Eichenfield LF, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition. Allergy. 2023;78(11):2875\u201391. https:\/\/doi.org\/10.1111\/all.15811.","journal-title":"Allergy"},{"issue":"24","key":"917_CR86","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"10086","key":"917_CR87","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"6","key":"917_CR88","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888\u201399. https:\/\/doi.org\/10.1111\/bjd.21867.","journal-title":"Br J Dermatol"},{"issue":"3","key":"917_CR89","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20810","volume":"186","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Beck LA, de Bruin WM, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453\u201365. https:\/\/doi.org\/10.1111\/bjd.20810.","journal-title":"Br J Dermatol"},{"key":"917_CR90","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5414\/ALX02272E","volume":"5","author":"S Traidl","year":"2021","unstructured":"Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergol Select. 2021;5:293\u2013304. https:\/\/doi.org\/10.5414\/ALX02272E.","journal-title":"Allergol Select."},{"key":"917_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.03.035","author":"YS Pathania","year":"2023","unstructured":"Pathania YS. JAK inhibitors in atopic dermatitis associated with risk of viral infections: A critical appraisal. Actas Dermosifiliogr. 2023. https:\/\/doi.org\/10.1016\/j.ad.2022.03.035.","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"917_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100195","volume":"3","author":"M Kamata","year":"2023","unstructured":"Kamata M, Tada Y. Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence. JID Innov. 2023;3(3): 100195. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100195.","journal-title":"JID Innov."},{"issue":"18","key":"917_CR93","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.2217\/imt-2023-0078","volume":"15","author":"F Antonelli","year":"2023","unstructured":"Antonelli F, Malvaso D, Caldarola G, Simone C, Peris K, Chiricozzi A. Infectious adverse events in patients with atopic dermatitis treated with baricitinib. Immunotherapy. 2023;15(18):1521\u20139. https:\/\/doi.org\/10.2217\/imt-2023-0078.","journal-title":"Immunotherapy"},{"issue":"6","key":"917_CR94","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40257-023-00809-0","volume":"24","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Armstrong A, Blauvelt A, Reich K. Assessment of efficacy and safety outcomes beyond week 16 in clinical trials of systemic agents used for the treatment of moderate to severe atopic dermatitis in combination with topical corticosteroids. Am J Clin Dermatol. 2023;24(6):913\u201325. https:\/\/doi.org\/10.1007\/s40257-023-00809-0.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"917_CR95","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/ijd.15853","volume":"61","author":"H Wood","year":"2022","unstructured":"Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol. 2022;61(6):746\u201354. https:\/\/doi.org\/10.1111\/ijd.15853.","journal-title":"Int J Dermatol"},{"key":"917_CR96","doi-asserted-by":"publisher","first-page":"8382761","DOI":"10.1155\/2021\/8382761","volume":"2021","author":"HA Fadlalmola","year":"2021","unstructured":"Fadlalmola HA, Albadrani MS, Elhusein AM, Mohamedsalih WE, Swamy VDS, Mamanao DM. Effectiveness and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of randomized clinical trials. Dermatol Res Pract. 2021;2021:8382761. https:\/\/doi.org\/10.1155\/2021\/8382761.","journal-title":"Dermatol Res Pract"},{"issue":"5","key":"917_CR97","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707. https:\/\/doi.org\/10.1007\/s40257-021-00618-3.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"917_CR98","doi-asserted-by":"publisher","first-page":"2200866","DOI":"10.1080\/09546634.2023.2200866","volume":"34","author":"C Flohr","year":"2023","unstructured":"Flohr C, Cork MJ, Ardern-Jones MR, et al. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. J Dermatolog Treat. 2023;34(1):2200866. https:\/\/doi.org\/10.1080\/09546634.2023.2200866.","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"917_CR99","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2019380.","journal-title":"N Engl J Med"},{"issue":"10348","key":"917_CR100","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(22)01199-0.","journal-title":"Lancet"},{"issue":"9","key":"917_CR101","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/jdv.18193","volume":"36","author":"T Werfel","year":"2022","unstructured":"Werfel T, Irvine AD, Bangert C, et al. An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36(9):1486\u201396. https:\/\/doi.org\/10.1111\/jdv.18193.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"917_CR102","doi-asserted-by":"publisher","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","volume":"34","author":"T Bieber","year":"2023","unstructured":"Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2023;34(1):2161812. https:\/\/doi.org\/10.1080\/09546634.2022.2161812.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"917_CR103","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s12325-023-02445-w","volume":"40","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Bieber T, Alten R, et al. Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications. Adv Ther. 2023;40(4):1867\u201383. https:\/\/doi.org\/10.1007\/s12325-023-02445-w.","journal-title":"Adv Ther"},{"issue":"1","key":"917_CR104","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23\u201332. https:\/\/doi.org\/10.1093\/bjd\/ljad096.","journal-title":"Br J Dermatol"},{"issue":"10290","key":"917_CR105","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"issue":"1","key":"917_CR106","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151(1):172\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.023.","journal-title":"J Allergy Clin Immunol"},{"key":"917_CR107","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdin.2021.11.001","volume":"6","author":"N Katoh","year":"2022","unstructured":"Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis. JAAD Int. 2022;6:27\u201336. https:\/\/doi.org\/10.1016\/j.jdin.2021.11.001.","journal-title":"JAAD Int."},{"issue":"10290","key":"917_CR108","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4.","journal-title":"Lancet"},{"issue":"9","key":"917_CR109","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"917_CR110","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.clinthera.2019.01.010","volume":"41","author":"L Galli","year":"2019","unstructured":"Galli L, Venturini E, Bassi A, et al. Common community-acquired bacterial skin and soft-tissue infections in children: an intersociety consensus on impetigo, abscess, and cellulitis treatment. Clin Ther. 2019;41(3):532-51e17. https:\/\/doi.org\/10.1016\/j.clinthera.2019.01.010.","journal-title":"Clin Ther"},{"key":"917_CR111","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13017-018-0219-9","volume":"13","author":"M Sartelli","year":"2018","unstructured":"Sartelli M, Guirao X, Hardcastle TC, et al. 2018 WSES\/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg. 2018;13:58. https:\/\/doi.org\/10.1186\/s13017-018-0219-9.","journal-title":"World J Emerg Surg."},{"key":"917_CR112","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12875-014-0175-8","volume":"15","author":"EM van Bijnen","year":"2014","unstructured":"van Bijnen EM, Paget WJ, den Heijer CD, et al. Primary care treatment guidelines for skin infections in Europe: congruence with antimicrobial resistance found in commensal Staphylococcus aureus in the community. BMC Fam Pract. 2014;15:175. https:\/\/doi.org\/10.1186\/s12875-014-0175-8.","journal-title":"BMC Fam Pract"},{"issue":"2","key":"917_CR113","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147\u201359. https:\/\/doi.org\/10.1093\/cid\/ciu296.","journal-title":"Clin Infect Dis"},{"issue":"45","key":"917_CR114","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3238\/arztebl.m2022.0308","volume":"119","author":"R Leistner","year":"2022","unstructured":"Leistner R, Hanitsch LG, Kruger R, Lindner AK, Stegemann MS, Nurjadi D. Skin infections due to panton-valentine leukocidin-producing S. aureus. Dtsch Arztebl Int. 2022;119(45):775\u201384. https:\/\/doi.org\/10.3238\/arztebl.m2022.0308.","journal-title":"Dtsch Arztebl Int"},{"issue":"8","key":"917_CR115","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ijd.14079","volume":"57","author":"AK Guzman","year":"2018","unstructured":"Guzman AK, Schairer DO, Garelik JL, Cohen SR. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. Int J Dermatol. 2018;57(8):1001\u20136. https:\/\/doi.org\/10.1111\/ijd.14079.","journal-title":"Int J Dermatol"},{"issue":"5","key":"917_CR116","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/bf00373427","volume":"287","author":"O B\u00e4ck","year":"1995","unstructured":"B\u00e4ck O, Scheynius A, Johansson SG. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res. 1995;287(5):448\u201351. https:\/\/doi.org\/10.1007\/bf00373427.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"917_CR117","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.idh.2019.02.002","volume":"24","author":"M Kilpatrick","year":"2019","unstructured":"Kilpatrick M, Hutchinson A, Bouchoucha SL. Nurse\u2019s perceptions on infection prevention and control in atopic dermatitis in children. Infect Dis Health. 2019;24(3):141\u20136. https:\/\/doi.org\/10.1016\/j.idh.2019.02.002.","journal-title":"Infect Dis Health."},{"issue":"5","key":"917_CR118","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1590\/s0365-05962012000500010","volume":"87","author":"V Petry","year":"2012","unstructured":"Petry V, Bessa GR, Poziomczyck CS, et al. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012;87(5):729\u201334. https:\/\/doi.org\/10.1590\/s0365-05962012000500010.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"917_CR119","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18(3):253\u201361. https:\/\/doi.org\/10.1080\/1744666X.2022.2014323.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"917_CR120","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"Chu DK, Panel AAJADG, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312. https:\/\/doi.org\/10.1016\/j.anai.2023.11.009.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"917_CR121","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102.","journal-title":"J Am Acad Dermatol"},{"key":"917_CR122","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: version 2.1. 2022. https:\/\/www.guidelines.edf.one\/uploads\/attachments\/clbm6nh6x07tw0d3qtyb1ukrt-0-atopic-eczema-gl-full-version-dec-2022.pdf. Accessed 7 Oct 2024."},{"key":"917_CR123","unstructured":"European Medicines Agency. Cibinqo summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf. Accessed 22 Oct 2024."},{"key":"917_CR124","unstructured":"European Medicines Agency. Olumiant summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf. Accessed 22 Oct 2024."},{"key":"917_CR125","unstructured":"European Medicines Agency. Rinvoq summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf. Accessed 22 Oct 2024."},{"issue":"1","key":"917_CR126","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, Dorner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218398.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"917_CR127","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/QCO.0000000000000635","volume":"33","author":"JF Jabbour","year":"2020","unstructured":"Jabbour JF, Sharara SL, Kanj SS. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. Curr Opin Infect Dis. 2020;33(2):146\u201354. https:\/\/doi.org\/10.1097\/QCO.0000000000000635.","journal-title":"Curr Opin Infect Dis"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00917-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00917-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00917-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T08:27:49Z","timestamp":1740385669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00917-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":127,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["917"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00917-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"6 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work, medical writing assistance for the development of this article and the Open Access Fee was funded by Sanofi, Italy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Maria Esposito has served as a speaker or board member for AbbVie, Almirall, Amgen, Eli Lilly, LEO Pharma, Janssen, Novartis, Pfizer, Sanofi and UCB. Maria Concetta Fargnoli has served as an advisory board member for AbbVie, LEO Pharma, Novartis and Sanofi. Caterina Foti has acted as a speaker, consultant and advisory board member for AbbVie, Amgen, LEO Pharma, Novartis and Sanofi. Giampiero Girolomoni has served on boards for, received research grants from and received personal fees\/honoraria for lectures from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung Bioepis and Sanofi. Paolo Matruglio and Elena Nicoli are employees of Sanofi and may hold shares and\/or stock options in the company. Maddalena Napolitano has acted as speaker, consultant and advisory board member for AbbVie, Amgen, Eli Lilly, LEO Pharma, Pierre Fabre and Sanofi. Paolo Romita declares no potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"M.N., M.E., M.C.F., G.G., P.R. and C.F. contributed to review conception. All authors contributed to the selection of the literature. All authors critically revised the manuscript for intellectual content between drafts and approved the final version for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}